Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027819 (neuroblastoma)
 27,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seventy-two children with recurrent, progressive, or metastatic lymphomas and other solid tumors, exclusive of primary central nervous system (CNS) tumors, were treated with aziridinylbenzoquinone (AZQ, diaziquone) at 9 mg/m2/day by 30-min intravenous infusion for 5 days every 3 weeks. Fifty-four patients were evaluable for response. Three partial responses occurred, two in patients with recurrent Hodgkin's disease and one in a patient with intraocular retinoblastoma. Sufficient numbers of patients with osteosarcoma, neuroblastoma, and Wilms' tumor were evaluable to demonstrate inactivity of this dosing regimen in these tumor types. Numbers of evaluable patients for other tumor types were insufficient to conclusively demonstrate inactivity. Myelosuppression, which was profound and prolonged, was observed. As administered in this study, AZQ has marginal activity and severe myelotoxicity in children with solid tumors.
 ...
PMID:A phase II study of diaziquone in children with recurrent or progressive solid tumors. Report from the Childrens Cancer Study Group. 224 Apr 75

Retinoblastoma and neuroblastoma have many common characteristics. There are conflicting reports of the effectiveness of vitamin B12 in the therapy of neuroblastoma. Where conventional therapy has failed in the treatment of intraocular retinoblastoma, a trial of vitamin B12 is suggested.
 ...
PMID:Rationale for vitamin-B12 treatment of retinoblastoma. 1687 96